These 5 stocks that are drawing attention

The U.S. markets continued their weak trend on Wednesday, with the Federal Open Market Committee meeting next week beginning to weigh on investors minds. The S&P 500 and the Nasdaq closed in the red, while the Dow ended the session flat. Here are five stocks that are drawing retail investors attention:

The EV-maker's shares of Tesla Inc TSLA were 3.21% lower on Wednesday. The company has started bookings for its vehicles in Thailand, Southeast Asia's largest market for passenger electric cars, ruled by its Chinese rivals. According to Yvonne Chan, Thailand's country director, Tesla will deliver its Model 3 and Model Y cars in the first quarter of next year.

Apple Inc. AAPL: Apple shares were 1.38% lower on Wednesday. A French environmental campaign group has filed a complaint against the iPhone maker over commercial practices that restrict the use of spare parts for repairs, according to a report by Reuters.

The HOP association said in a statement that in many of the cases documented in the complaint, malfunctions are found in cases in which the device is repaired with a part, even an identical and original part, not authorized by Apple's software.

GameStop Corp. GME: GameStop shares closed 4.83% lower but gained 3.5% in extended trading on Wednesday. GameStop reported third-quarter revenue of $1.186 billion, a decrease from $1.297 billion a year ago and below average analyst estimates of $1.35 billion.

Prometheus Biosciences Inc RXDX: Shares of Prometheus soared 165.67% on Wednesday and added 3.32% in extended trading. The company reported encouraging results from ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2 studies of PRA 023 for ulcerative colitis and Crohn's disease. The company intends to offer and sell $250 million of shares of its common stock in an underwritten public offering.

The shares of the company closed 9.79% higher on Wednesday, according to Cassava Sciences Inc. The clinical-stage biotechnology company announced the completion of drug administration in an open-label study of simufilam for Alzheimer's Disease on December 6.